Christel Celeste Bastida - Publications

Affiliations: 
University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Neuroendocrinology, Cancer, Phase I Clinical Trials, Reconstructive Surgery, Patient-reported outcomes

10/18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale Journal of Pain. DOI: 10.1016/j.jpain.2015.07.002  0.68
2014 Bastida CC, Puga F, Gonzalez-Lima F, Jennings KJ, Wommack JC, Delville Y. Chronic social stress in puberty alters appetitive male sexual behavior and neural metabolic activity. Hormones and Behavior. 66: 220-7. PMID 24852486 DOI: 10.1016/j.yhbeh.2014.05.002  0.68
2014 Falchook GS, Lippman SM, Bastida CC, Kurzrock R. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head & Neck. 36: E25-7. PMID 23852769 DOI: 10.1002/hed.23429  0.68
2013 Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 3004-11. PMID 24158411 DOI: 10.1093/annonc/mdt395  0.68
2013 Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 4: 310-5. PMID 23470635  0.68
2013 Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: e19-20. PMID 23328556 DOI: 10.1097/JTO.0b013e31827ce38e  0.68
2012 Arendt DH, Smith JP, Bastida CC, Prasad MS, Oliver KD, Eyster KM, Summers TR, Delville Y, Summers CH. Contrasting hippocampal and amygdalar expression of genes related to neural plasticity during escape from social aggression. Physiology & Behavior. 107: 670-9. PMID 22450262 DOI: 10.1016/j.physbeh.2012.03.005  0.68
2009 Bastida CC, Puga F, Delville Y. Risk assessment and avoidance in juvenile golden hamsters exposed to repeated stress. Hormones and Behavior. 55: 158-62. PMID 18948107 DOI: 10.1016/j.yhbeh.2008.09.009  0.68
2007 Puga F, Barrett DW, Bastida CC, Gonzalez-Lima F. Functional networks underlying latent inhibition learning in the mouse brain. Neuroimage. 38: 171-83. PMID 17703956 DOI: 10.1016/j.neuroimage.2007.06.031  0.68
2006 Taravosh-Lahn K, Bastida C, Delville Y. Differential responsiveness to fluoxetine during puberty. Behavioral Neuroscience. 120: 1084-92. PMID 17014259 DOI: 10.1037/0735-7044.120.5.1084  0.68
Low-probability matches
2014 Bastida C, Amorós P, Castro P, Soy D. Tractament de la malària greu. A propòsit d'un cas Circular Farmaceutica. 72: 29-33.  0.12
2009 Bastida C, Holguín-Veras J. Freight generation models: Comparative analysis of regression models and multiple classification analysis Transportation Research Record. 51-61. DOI: 10.3141/2097-07  0.08
2013 Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer Oncotarget. 4: 118-127. PMID 23435217  0.04
2015 Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Seminars in Oncology. 42: 832-48. PMID 26615129 DOI: 10.1053/j.seminoncol.2015.09.022  0.01
2015 Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. The Journal of Pain : Official Journal of the American Pain Society. PMID 26210041 DOI: 10.1016/j.jpain.2015.07.002  0.01
2014 Falchook GS, Ordóñez NG, Bastida CC, Stephens PJ, Miller VA, Gaido L, Jackson T, Karp DD. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 25366691 DOI: 10.1200/JCO.2013.50.5016  0.01
2014 Bastida C, Also MA, Pericas JM, Letang E, Tuset M, Miró JM. Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients? | Rabdomiólisis y hepatotoxicidad grave por interacción entre ritonavir y simvastatina. ¿Puede emplearse la estatina más coste-efectiva en todos los pacientes infectados por el virus de la inmunodeficiencia humana? Enfermedades Infecciosas Y Microbiologia Clinica. 32: 579-582. DOI: 10.1016/j.eimc.2014.03.014  0.01
2014 Manzaneque A, Bastida C, Rovira M, Clos J. Tractament farmacològic de la bufeta hiperactiva Circular Farmaceutica. 72: 21-26.  0.01
Hide low-probability matches.